Medexus Pharmaceuticals Inc. (OTCQX:MEDXF) Q2 2025 Earnings Conference Call November 8, 2024 8:00 AM ET
Company Participants
Victoria Rutherford – IR, Adelaide Capital
Ken d’Entremont – CEO
Brendon Bushman – CFO
Conference Call Participants
Andre Uddin – Research Capital
Michael Freeman – Raymond James
Max Czmielewski – Ventum Capital Markets
Justin Keywood – Stifel
Operator
Good morning everyone and welcome to the Medexus Pharmaceuticals Second Quarter 2025 Conference Call. At this time, all participants are in a listen-only mode and we will open for questions following the presentation. [Operator Instructions] Please note, this conference is being recorded.
I will now turn the conference over to your host Victoria Rutherford, Investor Relations. Victoria, the floor is yours.
Victoria Rutherford
Thank you and good morning everyone. Welcome to Medexus Pharmaceuticals second fiscal quarter 2025 earnings call. On the call this morning are Kenneth d’Entremont, Chief Executive Officer and Brendon Buschman, Chief Financial Officer. If you have any questions after the call or would like further information about the company, please contact Adelaide Capital at 480-625-5772.
I would like to remind everyone that this discussion will include forward-looking information as defined in securities laws. Actual results may differ materially from historical results or results anticipated by the forward-looking information.
In addition, the discussion will also include non-GAAP measures, such as adjusted net income and loss and adjusted EBITDA, which do not have any standardized meaning under IFRS and therefore, may not be comparable to similar measures presented by other companies.
For more information about forward looking information and non-GAAP measures, including reconciliations to net income and loss, please refer to the company’s MD&A, which along with the financial statements, is available on the company’s website at www.medexus.com and on SEDAR+ at www.sedarplus.ca. As a reminder, Medexus reports on the March 31st fiscal year
Read the full article here
